UCL also report creatinine rises on #ribociclib on poster 58. Much like @hflint.bsky.social's poster for #abemaciclib last year. I was confused by a recent message 🗞️ about this which used the global yellow card data...

Bart's are also reporting their #ribociclib data. Again too early for outcomes but they look at their ethnicity (as did UCL) and their ALT rises in poster 61. They don't report higher ALT rises which is interesting but they do report more fatigue. Are we asking the same question?

No surprise to also see some adjuvant #ribociclib posters. Too early (and too small numbers for single centre data) to have outcomes. But some #RWE suggesting more transaminitis (but n=10) in the real world from poster 49 at UCL.